SOTIO’s DCVAC/OvCa Significantly Improves Survival in Patients with Recurrent Ovarian Cancer
SOTIO, a biotechnology company owned by the PPF Group, presented results from SOV02, its Phase II clinical trial evaluating DCVAC/OvCa, an active cellular immunotherapy product, in patients with recurrent ovarian cancer at 2019 SGO’s 50 th Annual Meeting on Women's Cancer today. Final analysis of SOV02 shows that DCVAC/OvCa decreased the risk of death significantly compared to patients who did not receive DCVAC/OvCa. Clinical trial results were presented during today’s SGO 2019 Plenary Session by SOV02 principal investigator David Cibula, MD, PhD from General University Hospital in Prague (Czech Republic).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190319005837/en/
In the randomized, open label SOV02 clinical trial, patients with recurrent ovarian cancer received DCVAC/OvCa in combination with platinum-based chemotherapy. Compared to patients who did not receive DCVAC, it decreased the risk of death by 62%. The combination of chemotherapy and immunotherapy corresponded with 73% survival at two years, compared to 41% survival when chemotherapy was used alone. Overall survival results are statistically significant with a p-value of 0.0032. Progression Free Survival (PFS) increased from 9.5 to 11.3 months. Treatment with DCVAC/OvCa was very well tolerated and did not lead to any treatment discontinuation.
“Results from final data analysis of SOV02 clinical trial show that patients with recurrent ovarian cancer treated with DCVAC/OvCa are living significantly longer than patients in the control group. This outcome stands out very positively in this highly competitive clinical development landscape,” said David Cibula, MD, PhD, General University Hospital (Prague, Czech Republic), Past-President of European Society of Gynaecological Oncology (ESGO), principal investigator of SOV02 study.
Radek Spisek, MD, PhD, Chief Executive Officer of SOTIO commented: “We are very happy that the results of SOV02 study in the second line treatment of ovarian cancer confirm the promising data of SOV01 trial in the first line, reported at ASCO 2018. In cooperation with ENGOT, we are now setting up the design of the pivotal trial that will build on the results of the Phase II program. With the development of DCVAC/OvCa and the latest result we are addressing the medical need in this harmful disease.”
More information and details about the SOV02 clinical trial results can be found in the slides from the oral presentation at SGO 2019 posted on SOTIO’s webpage.
About SOV02 clinical trial:
SOV02 is a randomized, open-label, parallel-group, multi-center Phase II clinical trial evaluating the effect of adding DCVAC/OvCa to standard chemotherapy (carboplatin and gemcitabine) in women with first relapse of platinum-sensitive epithelial ovarian cancer.
Head of Communication
T: (+420) 224 174 448
M: (+420) 603 280 971
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Masergy Releases 2019 SD-WAN Market Trends Report16.7.2019 11:00:00 CEST | Press release
Masergy, a leading provider of managed SD-WAN, cloud communications and managed security solutions, today announced results from its new 2019 SD-WAN Market Trends Survey, which found that security drives selection, skills gaps remain a primary obstacle to adoption, and adoption continues to rise. The survey, conducted in partnership with IDG Research, analyzed responses from IT decision makers in global enterprises across a variety of industries. This survey was also conducted in 2017 as a benchmark in order to measure SD-WAN trends over time. Optimizing the network to support cutting-edge technology stands out as the most prominent objective that was covered in the survey. Most survey participants find that security is the biggest WAN challenge, even outweighing cost concerns. Managing numerous users, devices, and locations is also an increasing pain point. Key findings from the 2019 survey include: ● Optimizing the network to support cutting-edge technologies remains the top WAN obje
LuxTrust and Cambridge Blockchain Announce Private Beta for Privacy-Protecting Identity Platform IDKEEP16.7.2019 10:50:00 CEST | Press release
LuxTrust S.A., a leading Digital Trust Services Provider in Luxembourg, and Cambridge Blockchain Inc. , a pioneer in digital identity enterprise Software, announced the private beta-testing phase for privacy-protecting European identity platform IDKEEP . Designed to resolve identity and personal-data related challenges faced by many digital service providers — such as banks and financial services, insurance, and healthcare, among others—IDKEEP is a huge step forward towards data ownership and control. The platform provides end users with full control over personal data and over sharing such data with services online, helping digital organizations to effectively manage consent as per GDPR rules and effectively manage validated users’ data, enabling trusted transactions online. In addition, IDKEEP opens a marketplace for data validators who can leverage a network effect of a large customer base, realizing efficiencies and re-use of expensive data validation processes. IDKEEP was develope
Wildz Casino Leads the Way in iGaming Machine Learning and Automation16.7.2019 09:00:00 CEST | Press release
As iGaming continues to expand into new global markets, Wildz Casino has entered the game at a time when innovation and ‘Machine Learning’ are emerging as dominant factors in this industry. Powered by a Rootz platform allowing for full automation, early signs are promising. Optimisation based on customer preferences has increased player value by 27% with streamlined, automated processes improving efficiency in all facets of the business. In today’s iGaming industry, it appears the innovative team behind Wildz.com are leading the charge into a ‘Machine Learning’ assisted future. By 2025, the global AI market is projected to be valued at almost $60 billion compared to $1.4 billion just a few years ago. Compared to competitors, Wildz has entered the market early. The result? A perfectly functioning machine, easy on the eye, with superb player incentives and an unrivalled Loyalty+ programme. Wildz by Rootz is powering Machine Learning and Automation into the iGaming future. Learn more abou
LifeSpan BioSciences Announces the Acquisition of Everest Biotech16.7.2019 08:00:00 CEST | Press release
LifeSpan BioSciences (LSBio™), a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Everest Biotech. Everest Biotech are ISO 9001:2015 certified experts in antigen affinity purified goat polyclonal antibodies. The acquisition of Everest Biotech further expands LSBio’s product offering and strengthens the company’s position as one of the fastest growing providers in the research reagent market. Through its partnerships, LSBio now offers a comprehensive catalogue of reagents that can be coupled with their extensive collection of IHC validated primary antibodies. “We are looking forward to adding the Everest Biotech product range to the LSBio portfolio,” said Heather Holemon, CEO of LSBio. “Everest Biotech products are of exceptionally high quality and perfectly complement our existing portfolio.” The Everest Biotech commitment to quality and continuous improvement has ensured the growth of their catalogue, which now contains thous
AppyParking Closes £7.6 Million Series A Funding16.7.2019 07:00:00 CEST | Press release
AppyParking, the kerbside management and mobility technology firm that is transforming parking for motorists and empowering local authorities and car park operators to better manage their assets, announced that the company has just closed a £7.6 million Series A round. The funding round includes new strategic investment from Hyundai Motor Company and Sumitomo Corporation. It was led by West Hill Capital, the London based venture capital firm, with participation from existing investors Aviva Ventures and Breed Reply. The investment brings AppyParking’s total funding since launch to over £11 million and will enable the company to accelerate product development, support domestic and international growth and continue to expand their talented team. Founded in 2013 with the launch of their award-winning smart parking app, AppyParking is on a mission to make parking forgettable and help prepare cities for the rise of autonomous vehicles. They were the first company in the world to focus on th
Dubai to Organise Global Investment in Aviation Summit in January 202016.7.2019 07:00:00 CEST | Press release
The General Civil Aviation Authority (GCAA) of UAE has announced that the second edition of Global Investment in Aviation Summit (GIAS) 2020, themed ‘Enabling Global Aviation Growth through Fund Raising and Key Partnerships’ will be held in Dubai from January 27-29. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190716005136/en/ Saif Mohammed Al Suwaidi, Director General of the GCAA (Photo: AETOSWire) Over 200 investors and 1,200 delegates, besides selected government officials, aviation organisations, finance & insurance firms, aviation asset owners, aircraft operators & logistic service providers and legal consultants are expected to turn up at the event. While disclosing the details of the summit Saif Mohammed Al Suwaidi, Director General of the GCAA, highlighted the UAE’s remarkable position in the international and regional aviation industry. Al Suwaidi said, “The national agenda for 2021 aims for UAE to be the world fi